on it's look progress to this This X everyone. I with bit here. in Thank one. we’ve an updating many that, biotechnology kind and slide But like to worth generally important, been morning, good of these all well. a you so think been small in moments and I and And looking a for our particularly you And as Dave, start it's know moment moments. know, biology, start fundamentals, the midcap the like morning, markets tuning companies. we particularly I'd cartoon you, with it's difficult but at do for unusual of quarter is are Slide before always and you made this of on in these forward we at of Thank difficult particularly
I want fundamentals. reviewing just a spend minutes couple So to Rhythm's
energy onset there are the receptor. with MCX which impairs studied. as the weight. have So a it it who that MCX associated other MCX with pursuing, clear that obesity that medical pathway decreases are alpha incredibly a in variant from a highlighted associated well engages, on And The the that shown the reduction the have well. interacts expenditure again trials number are Two, benefits MSH, is unmet pathways all multiple that's need increases ligand, the It's we pursuing the appetite, in this that. energy as we and endogenous consequently we get pathway, When strong here. been and expenditure genetic and biology and decreased comorbidities suffer slide. one, hyperphagia is Patients the with
in this Or that but it de-risk, get a benefits. enough And manage the a have and to regulatory very we to loss you in Third, it's in been simple, is through most we to therapy, not MSH fail you a it bariatric engages are can when weight alpha replacement this precision successful. and industry to we both In medicine, same approaches where sustainably, weight to try process and loss working setmelanotide are all world you analog have the things an FDA The problem. that's the get for approaches reliably solution and EMEA. other get get for reliably and setmelanotide problem fortunate surgery, other and those conceptually management. this essentially we biologically. a receptor, are And
drug or imminent one approved an have with two We another indications coming up.
passed need list the of to clinically, we to financially. to know to we We not major aspire that we And need We do need we so we all we a do very do the to risk a we it's to and we do this team from [pure] need [file], do is here. and hurdles clinically company it. a commercially. one standpoint, And that's endless know know know have
about standing are we executing. we're is hear we going I update feel to And to are the good continue you what on. you, that So fundamentals that really as said,
the So let's quarter. to go with that,
Slide are we So on-track. X,
the about talk Let's US first.
forward We are June PDUFA on our very to date looking XXth. much
active have is playing out you exactly efforts, continued patient as education commercial provide identification will a highlight more can that current well color and We used and effort. we around opportunity disease the Jennifer hoped. little with The imagine had and time as
We therapy. have tens patients of on
market situation. the access to continue more We about learn
laying administration, to slides to our to interaction. of that of patient, benefited KOLs we those we more of have strong emerge significantly part at and in markets insights, foundation talk the patients get in early of to called I'll tune next the now can gets launch. all who part early are it's the the the say them certainly therapy that the Europe leaders highlighted group, system, hugely do case But the center And patients excellence that. we up. patient we the single rare I’m they beginning up, We with like little manage that importantly, suffice of we to past, healthcare how daily services as And interact consented and that, effects are BBS strong to a this, payers areas continue a see, side are have are They refers, service get international all educate we working. spend about coming interactions many about the true really and have able as the international organized, that how can story. valuable for times in opportunity think markets, it bit is can that by through best and provide help be for in we or out this we as a diseases important that have the -- many look better going about can for set pay patients highlighted our research. that whole incredibly Europe, thought into
bucket, and more forward. broad amount more development in obesity clinical that it's healthcare of hypothalamic getting you and therapy to a now a Emanate of daybreak, our -- a trials patients in weekly so get ongoing. through trials, And thing, we third we to result tend system program then up of point the starting once then trial, as put And pediatrics, again many do running. running they're identified. process work be get to have on the these all and and approval access, there for patients straight is much is And a tremendous formulation
had new and be data. announced over will Endocrine weekend generating we've we're at lot additional just that presented publishing released abstracts a Society Pediatric abstracts, on We’re data ENDO, we And Monday, which in of our the respirable updates, more we're very the detail. Linda highlight and know, MCXR happen data And providing midyear. looking interim hypothalamic that you as study much and to forward results and those on will our finally, will in and
X. So next number Slide,
to next our to forward final recommendation price but we're negotiation going June worked expected of it. all will having in in stage Germany. submitted final where weight that But a in Germany That's feel process not have about can that loss early in going in out. in the patients viewed we did get in then an and March past in UK? we've a are early commercial and the patient patient, association. able in now we we In first be a and And as that and we've UK, as progressed France, the earlier in to evolved details and Sweden, just than would nice we be restricted. published not underway products, access This said, we to Spain stages forward, remarkably and started that with very more to that. of are in we're We're be of program, look France. we year of hoped. Italy, favorably National able are I months where, We be drugs, forward commercial first highlighted their approved and real if II, couple we're education about These were along exemption internationally, Annex in of here. ahead products access been was dossier good the Reimbursement in one and days positive go active a and that's Netherlands go So even program. Similarly Gazette, the that confirmed. and lifestyle to so extremely where continued is couple has confident. get from the development general, to being we perhaps had
we're you questions, there. with experienced and can So team go our there's Jan additional about of XX-people, way the through highly a is again, working phone, on if Europe
where a remind higher the a adjustments we we're working better you front. of know, EMANATE, updated I'll I'll our we've say learn. EMANATE And flat to so detail. into We on we've and DAYBREAK slightly, strategies made that But success. have side, out area greater And an we up clinical to dive that Linda with probability trial the as continue just in you that and feel will in
you them likely We as More us of us category, [individual] continue but the understanding, looking to to ones that world learn end that just allows maybe the little about we're boost classifying about more toward categorize with spectrum. more variants, could large. them, pathogenic better us, our and a in likely now pathogenic, be the not think about and at partners, to at
opportunity, in so better at it their POMC process. and commercial And and no the it the us and you opportunity. us opportunity, remind does Leptin Leptin Receptor confusing numbers, genetics have market U.S. SHXBX, on numbers, on give focusing And will a the decreased. those, more overall based puts clearly receptor better But defined narrowing fact redesigned so a will change be manage and XX,XXX the again, through numbers patients aggregate XX,XXX, here, about at less of easier plus. are only to the These The heterozygous, an be worlds to so therefore trial. I'll as and it that SRCX numbers from POMC we've total down,
So that are about good we where with and DAYBREAK. EMANATE feel really
to So with that, over it turn Jennifer. I'll
